FTC Chair Lina Khan (Michael Brochstein/Sipa USA)(Sipa via AP Images)
September 20, 2024 12:00 PM EDTUpdated 02:35 PM
Pharma
Law

FTC to sue ma­jor PBMs over in­sulin re­bates, claim­ing they in­flat­ed pa­tient cost

Drew Armstrong

Executive Editor

The Fed­er­al Trade Com­mis­sion said that it is su­ing the three ma­jor US phar­ma­cy ben­e­fit man­agers over their role in the in­sulin mar­ket, claim­ing that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times